Hi all,

I am currently a volunteer carrying out clinical trials. The treatment form is oral and at present is running blind. This means some tablets are active and others are placebo. I nor the trial clinic know what treatment I am on and I have unique trial number so I am a blind subject to, if that makes sense.

My treatment began last year,(more details on my profile about severity etc), on day one I took photos of skin condition, yes they are available, so I could keep a record of my wishful thinking.

I am pleased to say that I am totally clear, not a spot, not a flake. I am 11 months into the trials and still more to go. I have details of the trials and will release as much as the clinic will allow. I feel at this point there are no restrictions but please be patient. I am not one for holding back

Thadius

So, it's xmas time coming up and I've just started a new job ish (4 months) when I am at work I wear jeans and a jumper so no one sees my skin. This is good but the xmas party is coming up and because no one has seen any of me I have no idea what to wear out. I know this might sound silly but does anyone know if I can just put a lil make up on my arms? It wouldnt only be for a few hours. I've gone threw my life not showing my legs (even in the summer time) so as annoying as it still is it's okay and I can always wear tights. My arms have been fine all my life really. I don't wanna think too much about it coz I will stress and that's obviously not what I want to do but I get so sad not even being able to go and shop for something nice to wear out. Sorry if this sounds lame but no one else understands

This is the PSUMMIT II result. PSUMMIT I, was first reported here: Stelara and Psoriatic Arhtritis Phase 3 data

Janssen Research & Development, LLC (Janssen) announced today new findings from PSUMMIT II, a Phase 3 investigational study that showed patients with active psoriatic arthritis, including those previously treated with one to five tumor necrosis factor (TNF) inhibitors, receiving the interleukin (IL)-12/23 inhibitor STELARA® (ustekinumab) demonstrated significant improvements in signs and symptoms of the disease.  Significantly more patients receiving either STELARA 45 mg or 90 mg achieved at least a 20 percent improvement in signs and symptoms according to American College of Rheumatology criteria (ACR 20) at week 24, the primary endpoint, than did patients receiving placebo regardless of background methotrexate use.  During a late-breaker session of PSUMMIT 1, the initial Phase 3 study, investigators will present 52-week data that showed improvement in efficacy of STELARA over time in treating signs and symptoms of the disease.  These data are being presented at the 2012 Annual Meeting of the American College of Rheumatology.  

In the Phase 3 Multicenter, Randomized, Double-blind, Placebo‑controlled trial of Ustekinumab, a Fully Human anti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Active Psoriatic Arthritis Including Those Previously Treated with Biologic Anti-TNF-alpha Agent(s) (PSUMMIT II) study, patients with active psoriatic arthritis despite treatment with disease-modifying antirheumatic drugs (DMARDs), nonsteroidal anti-inflammatory drugs (NSAIDs) and/or anti-TNF-alpha therapy (not intended as a superiority or comparative claim versus TNF inhibitors) were randomized to receive subcutaneous STELARA 45 mg or 90 mg or placebo at weeks 0, 4 and then every 12 weeks.  At week 24, the primary endpoint was met as statistically significantly greater proportions of patients achieving ACR 20 responses (a standard measure of improvement in disease activity) were observed in patients receiving STELARA 45 mg (43.7 percent of patients) or STELARA 90 mg (43.8 percent of patients) compared with 20.2 percent of patients receiving placebo (P < 0.001 for both comparisons).  Among patients previously treated with TNF inhibitors, 36.7 percent of patients and 34.5 percent of patients receiving STELARA 45 mg or 90 mg, respectively, achieved ACR 20 at week 24 compared with 14.5 percent of patients receiving placebo (P = 0.006 for STELARA 45 mg, P = 0.011 for STELARA 90 mg).

"TNF inhibitors are the only approved biologic treatment option for psoriatic arthritis, but not all patients benefit from these currently available treatments," said Christopher Ritchlin, M.D., M.P.H., Professor of Medicine and Director of the Rheumatology Fellowship Program and the Clinical Immunology Research Center at the University of Rochester Medical Center, and lead study investigator.  "A biologic therapy with a different mechanism of action, like ustekinumab, which has shown benefit in the treatment of psoriatic arthritis in two Phase 3 studies, is exciting for the rheumatology community."

In PSUMMIT II, significantly greater proportions of patients receiving STELARA 45 or 90 mg achieved ACR 50 at week 24 compared with placebo (17.5 and 22.9 percent vs. 6.7 percent, P = 0.018 for STELARA 45 mg, P = 0.001 for STELARA 90 mg).  ACR 70 responses for both STELARA groups were greater, though not significantly, than for the placebo group at week 24.  Of patients with at least three percent body surface involvement of psoriasis at the start of PSUMMIT II, 51.3 percent and 55.6 percent of patients receiving STELARA 45 mg and 90 mg achieved at least a 75 percent improvement in psoriasis, respectively, as measured by the Psoriasis Area Severity Index (CASI 75), compared with five percent of patients receiving placebo (P < 0.001 for both comparisons).  Significant improvements from baseline to week 24 were also observed in physical function, as measured by the Health Assessment Questionnaire Disability Index (HAQ-DI), in the STELARA 45 mg and 90 mg treatment groups compared with placebo-treated patients (P = 0.001 for STELARA 45 mg, P < 0.001 for STELARA 90 mg).

Similar proportions of patients experienced at least one adverse event (AE) through week 16, the placebo-controlled period, among those receiving STELARA 45 mg (63.1 percent), STELARA 90 mg (60.6 percent) and placebo (54.8 percent) with infections being the most common AE.  Serious AEs reported among the groups were: STELARA 45 mg (zero percent), STELARA 90 mg (1.0 percent) and placebo (4.8 percent).  No cases of tuberculosis (TB), opportunistic infections, major adverse cardiovascular events (MACE) or deaths occurred.  Through week 24, one serious infection due to complications of pre-existent interstitial lung disease was reported in the placebo group and one skin malignancy (squamous cell carcinoma in situ) occurred in the STELARA 90 mg group.

Improvement of Signs and Symptoms by STELARA in Patients with Active Psoriatic Arthritis: Week 52 Results of the Phase 3, Multicenter, Double-blind, Placebo-controlled PSUMMIT I Study

Findings from the Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled trial of Ustekinumab, a Fully Human anti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Active Psoriatic Arthritis (PSUMMIT I) study are the focus of a late breaker oral presentation.  PSUMMIT I is evaluating the efficacy and safety of STELARA in patients with active psoriatic arthritis despite treatment with conventional therapy (anti-TNF-alpha naive) through 108 weeks.  Patients were randomized to receive subcutaneous STELARA 45 mg or 90 mg or placebo at weeks 0, 4 and then every 12 weeks.  At week 24, 42.4 percent and 49.5 percent of patients receiving STELARA 45 mg and 90 mg, respectively, achieved ACR 20, the primary endpoint, compared with 22.8 percent of patients receiving placebo (P < 0.001 for both comparisons).  Patients who qualified for early escape at week 16 were considered non-responders for the primary and major secondary analyses at week 24.  Following week 24 assessment, patients receiving STELARA 45 mg and 90 mg continued to receive every-12-week maintenance therapy, and placebo patients were crossed over to receive STELARA 45 mg induction (at weeks 24 and 28) and maintenance therapy every 12 weeks thereafter.  Observed data showed that signs and symptoms continued to increase between weeks 24 and week 52, with 55.7 percent, 60.3 percent and 65.2 percent of patients in the STELARA 45 mg, STELARA 90 mg and placebo crossover groups, respectively, demonstrating ACR 20 response.

"Long-term management of the signs and symptoms of disease is essential in the treatment of psoriatic arthritis, a systemic inflammatory disease that can be marked by chronic pain and dysfunction," said Arthur Kavanaugh, M.D., Professor of Medicine, and Director of the Center for Innovative Therapy at the University of California, San Diego, and co-principal investigator.  "These results build on previously reported 24-week data from the PSUMMIT I trial of ustekinumab and demonstrate efficacy and improvements in disease activity at one year for patients living with psoriatic arthritis."

ACR 50 and ACR 70 response rates increased from week 24 through week 52 among patients receiving STELARA maintenance therapy.  At week 24, among patients receiving STELARA 45 mg, 24.9 percent achieved ACR 50 compared with 8.7 percent in the placebo group (P < 0.001), which increased to 31.4 percent at week 52, and 12.2 percent achieved ACR 70 compared with 2.3 percent in the placebo group (P < 0.001) at week 24, which increased to 18 percent at week 52.  Similar changes were observed in the STELARA 90 mg group at week 24 as 27.9 percent achieved ACR 50 compared with 8.7 percent in the placebo group (P < 0.001), which increased to 37 percent at week 52, and 14.2 percent achieved ACR 70 compared with 2.3 percent in the placebo group (P < 0.001) at week 24, which increased to 21.2 percent at week 52.  Investigators also reported continued improvements in physical function and skin symptoms through the end of the study, with nearly half of patients demonstrating clinically meaningful change from baseline in HAQ-DI scores, and more than two-thirds of patients achieving PASI 75 at week 52.

Among study participants affected with enthesitis (inflammation of the entheses, the sites where tendons or ligaments attach to bone, n=425) or dactylitis (inflammation of the finger or toe, n=286) at baseline, patients receiving STELARA achieved clinically relevant improvements in both measures at week 24 and week 52.  At week 24, median percent changes in enthesitis scores (-42.9 for STELARA 45 mg and -50.0 for STELARA 90 mg) and dactylitis scores (-75.0 for STELARA 45 mg and -70.8 for STELARA 90 mg) were significantly higher than those seen for patients receiving placebo (P < 0.001 for all comparisons).  Improvements in enthesitis scores (-83.3, -74.2 and -87.5) and dactylitis scores (-100 in all patients) in the STELARA 45 mg, 90 mg and crossover groups, respectively, continued through week 52.

A similar proportion of patients experienced at least one AE or serious AE through week 16, the placebo-controlled period of PSUMMIT I.  Safety through week 52 was consistent with that observed during the placebo-controlled period between STELARA 45 mg and 90 mg groups in the incidence of AEs (66.8 percent and 64.7 percent, respectively) and serious AEs (5.9 percent and 3.4 percent, respectively).  No malignancies, cases of TB, opportunistic infections or deaths occurred through week 52.  Investigators reported three MACE in STELARA-treated patients in patients with multiple pre-existing cardiovascular risk factors.

Source: prnewswire.com

Cellceutix Corporation a clinical stage biopharmaceutical company focused on discovering small molecule drugs to treat unmet medical conditions, including drug-resistant cancers and autoimmune diseases, reports that the Company has signed an agreement with a European Union (EU) clinical site for a Proof-of-Concept (PoC) trial of Prurisol™, the Company’s lead drug candidate for the treatment of psoriasis. The trial, a double blind study, is planned for the first quarter of 2013 and will include patient dosing over a 30-day period with follow up visits over the next 30 days.  Cellceutix decided on this protocol after discussions with pharmaceutical industry executives and believes this is the quickest path to evaluate the efficacy of Prurisol in humans with the objective of bringing it to market and creating greater shareholder value.

“Our laboratory research showed Prurisol to visually eliminate all traces of psoriatic tissue in human xenograft models in a short period of time.  We are very optimistic that the lab research will be replicated in a clinical setting,” said Leo Ehrlich, Chief Executive Officer at Cellceutix.  “There are more than 2 million people in the United States that suffer from psoriasis with few effective therapies available.  We believe that a new therapeutic bridging that gap could generate sales in excess of $1 billion annually, so we are naturally eager to see the effectiveness of Prurisol in human trials.  The pharmaceutical industry bases the value of a new drug on market size and the therapeutic benefit to patients, so we consulted with industry leaders on the most expeditious manner to give them that information.  A PoC trial in Europe was the answer.  The trials early next year are another milestone for us to continue to build value for our shareholders.”

Source: cellceutix.com

Other posts on Cellceutix / Prurisol
https://psoriasisclub.org/showthread.php?tid=121
https://psoriasisclub.org/showthread.php?tid=599

Hello. New member here. Minor skin P, not so minor P Arthritis. I'm just poking around trying to better understand what I have going on and ways to solve it. I am seeing a Rumatoidologist. I'm interested in the more obscure ways that this effects me and those with it. And for some reason, I am compelled to use this smilie.

I am coming up in bruises where some of my psoriasis is?

Is this normal?

Hello,
I am a 50 year old dentist from Finland and I was recently diagnosed with plaque psoriasis. I got strong cortisone salves from my doctor and they have helped me a lot. I have rashes only on my arms, scalp and ears. I find skin conditions very unpleasant and that doesn't help me very much.

Hey guys, Im new to this site so just wanna say Hi first of all

My doctor has given me Diprobase cream but I was just wondering about other ways I could keep my skin moisturised and what do you guys use. Does baby oil help or could you gimme another suggestion? I did buy baby oil the other day it was only £1 so if it doesnt work then im not too bothered.
Thanks

Background:
Psoriasis is associated with an atherogenic lipid profile but longitudinal changes in lipids around disease onset are unknown. The purpose of our study is to examine the effect of psoriasis onset on serum lipid profiles.

Methods:
We compared changes in lipid profiles in a population based incident cohort of 689 patients with psoriasis and 717 non-psoriasis subjects. All lipid measures performed 5 years before and after psoriasis incidence/index date were abstracted. Random-effects models adjusting for age, sex and calendar year were used to examine trends in lipid profiles.

Results:
There were significant declines in total cholesterol (TC) and low-density lipoprotein (LDL) levels during the 5 years before and after psoriasis incidence/index date in both the psoriasis and the non-psoriasis cohorts, with a greater decrease noted in the TC levels (p=0.022) and LDL (p=0.054) in the non-psoriasis cohort. High-density lipoprotein (HDL) levels increased significantly both before and after psoriasis incidence date in the psoriasis cohort. Triglyceride (TG) levels were significantly higher (p<0.001), and HDL levels significantly lower (p=0.013) in patients with psoriasis compared to non-psoriasis subjects. There were no differences in prescriptions for lipid lowering drugs between the two cohorts.

Conclusions:
Patients with psoriasis had a significant decrease in TC and LDL levels during the 5 years before psoriasis incidence. Higher mean TG and lower mean HDL levels were noted in the 5 years before psoriasis incidence. These changes are unlikely to be caused by lipid lowering treatment alone and require further exploration.

Source: NO LINKS ALLOWED

About 7 years ago I got shingles from the waist down on my right side. As you all probably know, shingles attacks the nerve endings. What is interesting is that everywhere the shingles broke out that was already covered by psoriasis, the psoriasis is now gone (light brown discoloration). Almost like the shingles stopped the signal to stop producing extra skin cells in that area. My Dermatologist doesn't think much of it but I think that some research should go into this. I would say about 20% of my upper thigh no longer has psoriasis.

New to forum and wanted to say hi.

I have had psoriasis for twenty years (now in my late 40's). I have been on Enbrel for 14 years and tried every lotion under the sun. Have it on about 30% of body. Mostly from the waist down and elbows.

I was diagnosed with psoriasis arthritis on my knee and that is how I came to taking Enrel. It does a nice job of reducing swelling and took care of terrible sclap problem but that is about it.

The expensive lotions help but , well they are expensive. I mostly use coconut oil. I by the 16oz jar for about $5. Can be greasy but I always wipe down with towel and apply several times a day.

I am an avid boater so in the early spring my exposed areas look real good but eventually it catches up then flakes so I am left with a nice tan and white skin were skin flakes off. Oh well. Tanning helps in winter for me

English research on the use of dimethylfumarates with Multiple Sclerosis. I do not have a subscription so I cannot see the whole Articles. Heard about these articles in a meeting on.... Psoriasis.
Because, what is Multiple Sclerosis ? Right, an immune disease. And what is psoriasis...?

If you have some boards that you don't view often, or you want less scrolling on your screen. You can shrink some boards by clicking the little icon in the top right corner of your chosen board.

Click images to enlarge

Hi guys,

New user Not new to Psoriasis or PA though :(

My p is not normally too bad and tolerable - I have it restricted (for the last couple of years) to my elbows (the worst), scalp and belly button!
But as of late, probably in the last 6 months I have had episodes where the P on my elbows gets pustular plaques.. normal scales that are full of greenish puss . Before the pus turns up they get VERY itchy, hot and painful (you never realize how much pressure you put on your elbows until you can't!) It does not tend to last too long but is a bit concerning and I can't seem to finds much out there on what might be causing it. From what I have read and seen of Pustular Psoriasis I don't think it is that, although some of the symptoms that go with it rings some bells...??

Does this happen to anyone else? What triggers it? How can I stop it?? Do I need to see my Doctor?
I am not on any meds or creams (2 rounds of methodextrate(sp) cleared up almost all of it apart from the parts I mention above), I am currently using glycerin to keep it moisturized and I find this is working well and perhaps cleared some of it up.

Thanks in advance

Kiwi

Hey!!
New to this!!
Hoping to speak to people that understand the situation that I'm in. Ive got Psoriasis in my scalp and its spreading to the rest of my body!!
I've been given me different types of cream and I've been referred to a Derm, its spreading to parts of my body where i cant hide it! Its really embarrassing! My friends and family are saying its fine and no-one will notice but i know people are looking and its making me really paranoid!!
I know its getting worse by the day and people keep looking at me and its horrible. I can tell they are looking but trying to hide it!!
I just don't know what to do anymore!!
Should i be scared about seeing a derm??
What am i too expect?
Cheers guys x

Hi, I wish to show an image of my rash which I have taken and placed on my desktop. Can this be done please? Cheers

Right we are housebuilding - with very little money & it gets stressful, now I also have my husbands ex living with us - now I guess I have a right to be stressed?? not really, the house is brill, can't believe we've done this! Melly's ex is ok, we are finding our feet & she contributes to costs so I don;t have problem, she needs somewhere to be safe & Shasa their youngest has commented how much better she is, I'm the caring type so having someone who needs me is ok. Also she has taken over the hovering & loads the dishwasher etc... I cook she clears up - seems to work... so why are my friends telling me its wrong?? surely its not wrong to give someone somewhere to live when they have problems? I don;t feel able to talk to my friends as they all seem horrified? Its not as if its just us & her in the house, we also have 2 other lodgers, one of whom eats with us most nights, it makes life more interesting & I'll admit we are totally different & she gives me a totally different view of life at times! I need my friends support but find they can't see how this works - she is not the predatory type, if I said I was unhappy with the situation Melly would understand, but its not in my nature - so why the message? is it the stress of the situation or the feeling that my friends feel I'm being put upon that is making my foot worse - today its all around the edge & around my toes & feels like someone is pushing in nails when I walk - so I scratch.... ahhhh!! think its time for the saw.... sorry just miserable - and I have a low pain threshold which does not help! been on anti-depressents for long time, have been told not to come off again as I have a chemical imbalance, re-triggered by shingles so the glums are a fact of life, but I worry now that this very fact is making my psoriasis worse?? ahhh!! Fact of life the ex has to stay, I have no problem with her, I've no idea if she has a problem with me, but seems unlikely following the big hug I got the other day! so will someone just tell me I'm doing the right thing..... please

ok whinge over! feel better its off my chest (all 48D of it)

LEO Pharma Inc., a wholly owned U.S. subsidiary of LEO Pharma A/S, today announced that the U.S. Food and Drug Administration (FDA) approved Taclonex® (calcipotriene and betamethasone dipropionate) Topical Suspension, 0.005%/0.064% for the treatment of body plaque psoriasis. Taclonex® Topical Suspension is a first-line single treatment now indicated for both scalp and body plaque psoriasis for up to 8 weeks.

Taclonex® Topical Suspension is the only once-daily, steroid-containing topical treatment that combines the strength and benefits of 2 active ingredients, a vitamin D analog (calcipotriene) and a corticosteroid (betamethasone dipropionate). Taclonex® Topical Suspension requires only one prescription for both scalp and body treatment of plaque psoriasis. Patients using Taclonex® Topical Suspension may also be eligible to participate in LEO Quality Care™, a patient support program.

"A once-daily application makes Taclonex® Topical Suspension an effective, first-line choice of treatment for a significant number of psoriasis patients, with positive clinical results seen in a recent eight-week study," said Dr. Alan Menter, founder of the International Psoriasis Foundation. "In addition to its prior approval for use on the scalp, it has been shown to be safe and effective for use on the body."

In two Phase III clinical studies of more than 1,600 patients with psoriasis on the scalp, and one phase III clinical study of over 1100 patients with psoriasis on the body, a higher percentage of patients treated with Taclonex® Topical Suspension achieved controlled disease than either monotherapies or vehicle used alone. In clinical trials, the most common adverse reactions that occurred in >1% of subjects treated with Taclonex® Topical Suspension and at a rate higher than in subjects treated with vehicle were folliculitis and burning sensation of the skin.

"We are pleased to introduce Taclonex® Topical Suspension as part of our ongoing commitment to helping people achieve healthy skin," said John Koconis, president and chief executive officer of LEO Pharma Inc. "This most recent FDA approval offers a new, single treatment option for patients suffering from plaque psoriasis on both scalp and body locations, and we look forward to continuously driving patient-centered innovation in the field of dermatology in the years to come."

INDICATION AND USAGE
Taclonex® Topical Suspension is indicated for the topical treatment of plaque psoriasis of the scalp and body in patients 18 years and older. Apply Taclonex® Topical Suspension to affected areas once daily for up to 8 weeks. Treatment may be discontinued earlier, if cleared. Instruct patients not to exceed a maximum weekly dose of 100 g.

IMPORTANT SAFETY INFORMATION
FOR TOPICAL USE ONLY. Taclonex® Topical Suspension is not for oral, ophthalmic, or intravaginal use and should not be applied to the face, axillae, or groin. Do not use if atrophy is present at the treatment site.

Hypercalcemia and hypercalciuria have been observed with use of Taclonex® Topical Suspension. If hypercalcemia or hypercalciuria develop, discontinue treatment until parameters of calcium metabolism have normalized. Systemic absorption of topical corticosteroids can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for clinical glucocorticosteroid insufficiency. Use of topical corticosteroids may require that patients be periodically evaluated for HPA axis suppression and calcium abnormalities. If HPA axis suppression is documented, attempt to withdraw the drug, reduce the frequency of application, or substitute a less potent steroid. Cushing's syndrome, hyperglycemia, and unmasking of latent diabetes mellitus can also result from systemic absorption of topical corticosteroids.

In clinical trials, the most common adverse reactions that occurred in greater-than or equal to 1% of subjects treated with Taclonex® Topical Suspension and at a rate higher than in subjects treated with vehicle were folliculitis and burning sensation of the skin. Other less common adverse reactions (<1% but >0.1%) were, in decreasing order of incidence, acne, exacerbation of psoriasis, eye irritation, and pustular rash. Local adverse reactions may include atrophy, striae, telangiectasias, burning, itching, irritation, dryness, folliculitis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection, and miliaria and may be more likely with occlusive use or more potent corticosteroids. Some local adverse reactions may be irreversible.

Taclonex® Topical Suspension may cause eye irritation. Avoid eye exposure. Patients who apply Taclonex® Topical Suspension to exposed skin should avoid excessive exposure to either natural or artificial sunlight, including tanning booths, sun lamps, etc. There are no adequate and well-controlled studies of Taclonex® Topical Suspension in pregnant women. Taclonex® Topical Suspension should be used during pregnancy only if the potential benefit to the patient justifies the potential risk to the fetus. Because many drugs are excreted in human milk, caution should be exercised when Taclonex® Topical Suspension is administered to a nursing woman. The patient should be instructed not to use Taclonex® Topical Suspension on the breast when nursing. Safety and effectiveness of the use of Taclonex® Topical Suspension in pediatric patients have not been studied.

Every time I go for an appointment with my dermatologist she goes through the *Dermatology Life Quality Index (DLQI) form. And one of the questions is “Over the last week, how much has your skin influenced the clothes you wear” I always tick the “Not Relevant” box as I’m not into clothes that much.

But I have been giving it some thought after reading a post where Lady B the Stylist with Psoriasis (her words not mine) was talking about Woolly Tights.
I do have a Woolly Jacket I sometimes wear when I’m feeling cold, but I find that wool makes my skin to itchy, especially if I have a few plaques of psoriasis, which can get caught in the wool and end up weeping from the friction.

I mostly wear loose light coloured cotton and have recently found the joy of Bamboo Fibre for socks and duvet cover. A farmer’s wife near to us makes Cashmere socks and did give me a pair, very nice they was too, but at €18 per pair I found €2 Bamboo just as comfy. So I suppose Psoriasis does affect my choice of clothes after all, and I should tick the box "A Little"

What about you, does psoriasis affect your choice of clothes?


*You can find more about the Dermatology Life Quality Index (DLQI) here Dermatology Life Quality Index (DLQI)

TNF (Tumor necrosis factor) inhibitors are a modern popular choice for the treatment of PsA (psoriatic arthritis), and a report by Frost & Sullivan a growth partnership company, suggests there is a need for drug manufacturers to work harder on low cost alternatives. The research finds that psoriatic arthritis pharmacotherapeutics prescribed as add-on therapies to standard background therapy earned revenues of approximately $751.5 million in 2011, and is estimated to reach $1.3 billion in 2017.

"While TNF inhibitors have laid the groundwork for the next generation of effective, disease-modifying biologics, the need of the hour is patient-friendly options with improved profiles, such as oral administration or enhanced tolerability," said Frost & Sullivan Senior Industry Analyst Deborah Toscano. "These novel drugs could offer better long-term clinical outcomes."

"With the impending launch of three new therapies for the treatment of PsA in 2014, the awareness of PsA is expected to increase substantially," noted Toscano. "This will renew interest in PsA, as patients and physicians will finally be presented with alternative treatments."

"However, slow uptake of these new drugs by a conservative regulatory and medical community is likely until they are proven in the market. To gain end-user confidence, companies must make products with a high degree of safety, with significant clinical or economic benefits over TNF inhibitors."